Not Yet Recruiting PHASE1/PHASE2 INTERVENTIONAL 10-arm NCT06774664

A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases

A Randomized, Double-blind, Placebo-controlled Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SCTC21C in Subjects With Plasma Cell-driven Autoimmune Diseases

Sponsor: Sinocelltech Ltd.

Conditions IgA Nephropathy

Interventions SCTC21C

Updated 1 time since 2025 Last updated: Jan 8, 2025 Started: Jan 31, 2025 Primary completion: Sep 30, 2027 Completion: Mar 31, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on IgA Nephropathy, this trial is actively recruiting participants. The trial is conducted by Sinocelltech Ltd. and has accumulated 1 data snapshot since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

1 version recorded

Not Yet Recruiting — PHASE1/PHASE2 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sinocelltech Ltd.

Data source: Sinocelltech Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baotou, China , Beijing, China , Chengdu, China , Guangzhou, China , Hangzhou, China , Jinan, China , Nanchang, China , Nanning, China , Ningbo, China , Shanghai, China and 6 more locations